tradingkey.logo

enVVeno Medical Corp

NVNO
0.355USD
+0.013+3.74%
收盘 12/24, 13:00美东报价延迟15分钟
7.17M总市值
亏损市盈率 TTM

enVVeno Medical Corp

0.355
+0.013+3.74%

关于 enVVeno Medical Corp 公司

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

enVVeno Medical Corp简介

公司代码NVNO
公司名称enVVeno Medical Corp
上市日期May 31, 2018
CEOBerman (Robert A)
员工数量37
证券类型Ordinary Share
年结日May 31
公司地址70 Doppler
城市IRVINE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编92618
电话19492612900
网址https://envveno.com/
公司代码NVNO
上市日期May 31, 2018
CEOBerman (Robert A)

enVVeno Medical Corp公司高管

名称
名称/职务
职务
持股
持股变动
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
97.44K
--
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
11.15K
+7.73%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
9.29K
--
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
1.60K
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 12月4日 周四
更新时间: 12月4日 周四
持股股东
股东类型
持股股东
持股股东
占比
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
其他
68.33%
持股股东
持股股东
占比
Satterfield (Thomas A Jr)
9.02%
Perceptive Advisors LLC
8.70%
Kingdon Capital Management, L.L.C.
6.72%
The Vanguard Group, Inc.
4.26%
CM Management, LLC
2.97%
其他
68.33%
股东类型
持股股东
占比
Individual Investor
10.76%
Investment Advisor
10.13%
Private Equity
8.70%
Hedge Fund
7.28%
Investment Advisor/Hedge Fund
1.91%
Research Firm
1.34%
Venture Capital
0.21%
其他
59.67%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
76
5.69M
28.14%
-667.58K
2025Q2
75
3.80M
19.76%
-3.06M
2025Q1
73
3.82M
21.80%
-3.21M
2024Q4
75
4.44M
25.31%
-1.95M
2024Q3
71
5.27M
30.14%
+688.15K
2024Q2
65
3.79M
29.68%
-1.51M
2024Q1
67
4.10M
32.04%
-789.97K
2023Q4
59
4.71M
36.59%
+2.14M
2023Q3
57
2.68M
28.24%
-1.00M
2023Q2
55
2.71M
28.61%
-1.36M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Perceptive Advisors LLC
1.28M
6.68%
+1.28M
--
Jun 30, 2025
Kingdon Capital Management, L.L.C.
1.36M
7.06%
+500.00K
+58.19%
Sep 02, 2025
The Vanguard Group, Inc.
698.34K
3.63%
+97.43K
+16.21%
Jun 30, 2025
Westside Investment Management, LLC
279.52K
1.45%
+20.48K
+7.90%
Jun 30, 2025
Geode Capital Management, L.L.C.
199.51K
1.04%
+2.21K
+1.12%
Jun 30, 2025
J.P. Morgan Securities LLC
182.30K
0.95%
-11.91K
-6.13%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
iShares Micro-Cap ETF
占比0%
DFA Dimensional US Sustainability Core 1 ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
公告日期
类型
比率
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1
Nov 27, 2020
Merger
25→1

常见问题

enVVeno Medical Corp的前五大股东是谁?

enVVeno Medical Corp 的前五大股东如下:
Perceptive Advisors LLC持有股份:1.28M,占总股份比例:6.68%。
Kingdon Capital Management, L.L.C.持有股份:1.36M,占总股份比例:7.06%。
The Vanguard Group, Inc.持有股份:698.34K,占总股份比例:3.63%。
Westside Investment Management, LLC持有股份:279.52K,占总股份比例:1.45%。
Geode Capital Management, L.L.C.持有股份:199.51K,占总股份比例:1.04%。

enVVeno Medical Corp的前三大股东类型是什么?

enVVeno Medical Corp 的前三大股东类型分别是:
Satterfield (Thomas A Jr)
Perceptive Advisors LLC
Kingdon Capital Management, L.L.C.

有多少机构持有enVVeno Medical Corp(NVNO)的股份?

截至2025Q3,共有76家机构持有enVVeno Medical Corp的股份,合计持有的股份价值约为5.69M,占公司总股份的28.14%。与2025Q2相比,机构持股有所增加,增幅为8.37%。

哪个业务部门对enVVeno Medical Corp的收入贡献最大?

在--,--业务部门对enVVeno Medical Corp的收入贡献最大,创收--,占总收入的--%。
KeyAI